Please assess the completion status of the following clinical trial:

Trial Title: Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Patients who have been started on Vahelva Respimat in accordance with the approved label in Korea~* Age \>= 18 years at enrolment~* Patients who have signed on the data release consent form~Exclusion criteria:~* Patients with hypersensitivity to Vahelva Respimat or to any of the excipients.~* Patients with a history of hypersensitivity to atropine or its derivatives(e.g. ipratropium, oxitropium, glycopyrronium, clidinium, umeclidinium)~* Patients with asthma~* Current participation in other clinical trials

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination) (Type: None): Korean patients with COPD who are newly prescribed with Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination).

Based on this trial design, predict the completion outcome and termination type (if applicable).